MetaCap

Rallybio Balance Sheet

NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.47-0.05 (-0.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Rallybio financial position

At the end of fiscal 2025, Rallybio reported total assets of $62.3 million, down 8.6% from a year earlier against total liabilities of $4.3 million. Shareholders' equity stood at $58.0 million, or 93.1% of assets. The company held $31.4 million in cash and equivalents.

The current ratio (current assets divided by current liabilities) was 14.50, meaning short-term assets cover obligations due within a year.

Summary generated from market data by MetaCap's automated system. Methodology

Rallybio balance sheet (annual)

Rallybio annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31
Cash & Equivalents31.37M13.90M24.49M56.96M175.33M140.23M
Short-Term Investments23.36M51.61M85.44M112.04M0—
Total Current Assets61.25M67.84M114.79M179.50M180.87M141.26M
Property, Plant & Equipment23.00K115.00K246.00K385.00K511.00K287.00K
Total Assets62.26M68.11M115.62M180.44M182.19M141.86M
Accounts Payable126.00K278.00K976.00K1.11M603.00K1.58M
Total Current Liabilities4.22M6.24M9.26M10.74M6.55M5.84M
Total Liabilities4.30M6.45M9.44M11.12M6.58M5.86M
Shareholders' Equity57.96M61.65M106.18M169.32M175.60M136.00M
Retained Earnings-302.00M-293.02M-235.25M-160.68M-94.03M-47.01M
Net Cash (Debt)54.74M65.51M109.93M168.99M175.33M140.23M
Shares Outstanding5.28M5.19M37.83M37.84M32.13M23.41M

This table shows 6 annual periods of Rallybio's balance sheet, from FY 2025 back to FY 2020, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RLYB's reporting calendar. What is a balance sheet?

More financial data